November 25, 2025
Memory lane ends here
Ozempic does not slow Alzheimer's, study finds
Ozempic hype hits a wall — commenters say weight loss win, not a brain cure
TLDR: Novo Nordisk says Ozempic doesn’t slow Alzheimer’s after a two-year study. Commenters split between praising its big wins for weight, heart, and kidneys and asking why anyone expected a diet drug to fix dementia, while fact-check scuffles flare and Novo’s stock drops 6%.
The internet’s favorite weight‑loss shot just got a reality check: Ozempic didn’t slow Alzheimer’s after two years, says Novo Nordisk, and the comment section immediately grabbed popcorn. The loudest chorus? Folks like wonderwonder arguing the “extras” will boil down to a simple truth: obesity is bad, losing weight is good — and that’s enough to celebrate. Meanwhile, skeptics like KittenInABox ask the blunt question: Why did anyone expect a hunger‑taming drug to fix memory loss? Cue the mechanism‑mystery debate and a collective side‑eye at the hype machine.
Receipts arrived fast: GuB‑42 linked the official press release here and an ongoing study here. Then the fact‑check fireworks: lghh demanded numbers and sources after a sweeping claim about “frail young people” and exercise fixing everything, calling out vibes masquerading as data. Comic relief? megaman821’s “I can’t remember the source” while discussing trials for higher‑dose injections — a comment that instantly became a memory‑loss irony meme.
The mood: hype tempered, hope redirected. Ozempic also struck out in Parkinson’s, but the community notes its wins for heart and kidney health remain strong. Investors felt the whiplash — Novo’s stock slid 6% — and the memes wrote themselves: “Stonks forgot how to go up,” “Ozempic can’t fix your memory, just your fridge.” Verdict: Not a brain cure, still a blockbuster for bodies.
Key Points
- •Novo Nordisk reported that a two-year study found Ozempic did not slow Alzheimer’s disease progression.
- •Ozempic delivers about 15% average weight loss in obese patients.
- •Earlier expectations of neurological benefits have been tempered; Ozempic also did not slow neurodegeneration in Parkinson’s patients.
- •Evidence for Ozempic’s cardiovascular and kidney benefits remains more robust.
- •Novo Nordisk’s share price fell 6% following the announcement.